| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 08/05/2024 | 22:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ADTX | Aditxt Inc |
| 03/05/2024 | 20:14 | Business Wire | CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
| 03/05/2024 | 15:00 | Business Wire | Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
| 02/04/2024 | 14:30 | Business Wire | Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) | NASDAQ:ADTX | Aditxt Inc |
| 27/03/2024 | 13:36 | PR Newswire (US) | Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | NASDAQ:ADTX | Aditxt Inc |
| 07/03/2024 | 13:54 | PR Newswire (US) | For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy | NASDAQ:ADTX | Aditxt Inc |
| 04/03/2024 | 23:27 | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:ADTX | Aditxt Inc |
| 22/02/2024 | 23:21 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:ADTX | Aditxt Inc |
| 14/02/2024 | 15:26 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:ADTX | Aditxt Inc |
| 01/02/2024 | 14:00 | PR Newswire (US) | Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 | NASDAQ:ADTX | Aditxt Inc |
| 30/01/2024 | 14:30 | Business Wire | Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications | NASDAQ:ADTX | Aditxt Inc |
| 23/01/2024 | 22:18 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:ADTX | Aditxt Inc |
| 18/01/2024 | 22:30 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:ADTX | Aditxt Inc |
| 08/01/2024 | 14:30 | Business Wire | Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million | NASDAQ:ADTX | Aditxt Inc |
| 05/01/2024 | 14:30 | Business Wire | Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
| 02/01/2024 | 14:30 | Business Wire | Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement | NASDAQ:ADTX | Aditxt Inc |
| 29/12/2023 | 23:07 | Business Wire | Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
| 12/12/2023 | 14:30 | Business Wire | Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally | NASDAQ:ADTX | Aditxt Inc |
| 16/11/2023 | 22:30 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:ADTX | Aditxt Inc |
| 16/11/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:ADTX | Aditxt Inc |
| 13/11/2023 | 22:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ADTX | Aditxt Inc |
| 10/11/2023 | 00:04 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ADTX | Aditxt Inc |
| 06/10/2023 | 14:00 | GlobeNewswire Inc. | Aditxt, Inc. to Present at 8th Annual Dawson James Conference | NASDAQ:ADTX | Aditxt Inc |
| 05/10/2023 | 14:00 | Business Wire | Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform | NASDAQ:ADTX | Aditxt Inc |
| 22/09/2023 | 16:19 | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request | NASDAQ:ADTX | Aditxt Inc |
| 21/09/2023 | 15:35 | GlobeNewswire Inc. | Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference | NASDAQ:ADTX | Aditxt Inc |
| 08/09/2023 | 13:05 | Business Wire | Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023 | NASDAQ:ADTX | Aditxt Inc |
| 06/09/2023 | 22:30 | Business Wire | Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
| 01/09/2023 | 01:00 | Business Wire | Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules | NASDAQ:ADTX | Aditxt Inc |
| 18/08/2023 | 13:02 | Business Wire | Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale | NASDAQ:ADTX | Aditxt Inc |